Skip to main content
Clinical Trials/NL-OMON43339
NL-OMON43339
Completed
N/A

A Nutritional intervention study to evaluate the effect Of Bovine Lactoferrin on innate immunity in Elderly people - NOBLE

FrieslandCampina Nederland BV0 sites30 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
ontsteking
Sponsor
FrieslandCampina Nederland BV
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Age 65\-85 years (if sufficient candidate participants are available, subjects with a higher age (preferentially \>\<\=75 yr) will be included)
  • \* BMI 20\-30 kg/m2
  • \* Non\-smoking
  • \* Generally healthy as assessed by the NIZO lifestyle and health questionnaire (\*Verklaring leefgewoonten en gezondheid\*).
  • \* Regular and normal Dutch eating habits as assessed by the NIZO lifestyle and health questionnaire (3 main meals per day)
  • \* Veins suitable for cannulation (blood sampling)
  • \* Voluntary participation
  • \* Having given written informed consent
  • \* Willing to comply with study procedures
  • \* Accept use of all encoded data, including publication, and the confidential use and storage of all data for 15 years.

Exclusion Criteria

  • \* Having chronic inflammatory or autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease
  • \* Disease of GI tract (including major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, known or suspected gastrointestinal disorders, colon or GI tract cancer), liver, gall bladder, kidneys, thyroid gland
  • \* Immune\-compromised
  • \* Use of vitamin supplements containing vitamin D and not willing to discontinue this during the study
  • \* Use of anti\-inflammatory drugs (for corticosteroids and NSAIDs : frequency \>1 per week)
  • \* Use of immunosuppressive drugs
  • \* Excessive alcohol usage (\>3 consumptions/day or \>15 consumptions/week)
  • \* Participation in any clinical trial including blood sampling and/or administration of substances within 60 days before inclusion in this study
  • \* Use of hormonal replacement therapy
  • \* Mental status that is incompatible with the proper conduct of the study

Outcomes

Primary Outcomes

Not specified

Similar Trials